Tumor Biology

, Volume 35, Issue 6, pp 5993–6002 | Cite as

The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer

  • George Sgourakis
  • Aggeliki Papapanagiotou
  • Christos Kontovounisios
  • Michalis V. Karamouzis
  • Georgia Dedemadi
  • Constantine Goumas
  • Constantine Karaliotas
  • Athanasios G. Papavassiliou
Research Article


This pilot study aimed to determine the feasibility of serum neurotensin/IL-8 values being used as a screening tool for colorectal cancer. Fifty-six patients and 15 healthy controls were assigned to seven groups according to their disease entity based on theater records and histology report. Blood samples for neurotensin and IL-8 were measured using an enzyme-linked immunosorbent assay. There were no differences in the clinical and biochemical parameters of patients and controls. Group (p = 0.003) and age (p = 0.059, marginally significant) were independent predictors of neurotensin plasma values. Neurotensin (p = 0.004) and IL-8 (p = 0.029) differed between healthy and colorectal cancer patients. Neurotensin values differentiate the control group from all remaining groups. The value of plasma neurotensin ≤54.47 pg/ml at enrollment selected by receiver operating characteristic (ROC) curves demonstrated a sensitivity of 77 %, specificity of 90 %, and an estimate of area under ROC curve (accuracy) of 85 % in predicting colorectal cancer. At enrollment, the value of plasma IL-8 ≥8.83 pg/ml had a sensitivity of 85 %, specificity 80 %, and an estimate of area under ROC curve (accuracy) of 81 % in predicting colorectal cancer. IL-8 should be used complementary to neurotensin due to its lower specificity. None of the colorectal cancer patients displayed a combination of high neurotensin and low IL-8 values (beyond cutoffs). It seems that a blood neurotensin/IL-8 system may be used as a screening tool for colorectal cancer, but much has to be done before it is validated in larger-scale prospective studies.


IL-8 Neurotensin Colon cancer Rectal cancer Colorectal cancer screening Sensitivity and specificity 



The present work was funded by the Department of Biological Chemistry, University of Athens Medical School, Athens, Greece, annual budget 2012.

Conflicts of interest



  1. 1.
    Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.CrossRefPubMedGoogle Scholar
  2. 2.
    U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–37.CrossRefGoogle Scholar
  3. 3.
    Knudsen AB, Hur C, Gazelle GS, Schrag D, McFarland EG, Kuntz KM. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Ann Intern Med. 2012;157:611–20.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Hassan C, Giorgi Rossi P, Camilloni L, Rex DK, Jimenez-Cendales B, Ferroni E, et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced neoplasia, according to the type of screening test. Aliment Pharmacol Ther. 2012;36:929–40.CrossRefPubMedGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network (2013) Colorectal cancer screening (version 2.2013). Accessed 16 Dec 2013
  6. 6.
    Carraway RE, Plona AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006;27:2445–60.CrossRefPubMedGoogle Scholar
  7. 7.
    Bugni JM, Rabadi LA, Jubbal K, Karagiannides I, Lawson G, Pothoulakis C. The neurotensin receptor-1 promotes tumor development in a sporadic but not an inflammation-associated mouse model of colon cancer. Int J Cancer. 2012;130:1798–805.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Vincent JP. Neurotensin receptors: binding properties, transduction pathways, and structure. Cell Mol Neurobiol. 1995;15:501–12.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhao D, Zhan Y, Koon HW, Zeng H, Keates S, Moyer MP, et al. Metalloproteinase-dependent transforming growth factor-alpha release mediates neurotensin-stimulated MAP kinase activation in human colonic epithelial cells. J Biol Chem. 2004;279:43547–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Ehlers RA, Zhang Y, Hellmich MR, Evers BM. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun. 2000;269:704–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Ehlers 2nd RA, Bonnor RM, Wang X, Hellmich MR, Evers BM. Signal transduction mechanisms in neurotensin-mediated cellular regulation. Surgery. 1998;124:239–46. discussion 246–237.CrossRefPubMedGoogle Scholar
  12. 12.
    Zhao D, Keates AC, Kuhnt-Moore S, Moyer MP, Kelly CP, Pothoulakis C. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem. 2001;276:44464–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Bossard C, Souaze F, Jarry A, Bezieau S, Mosnier JF, Forgez P, et al. Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear beta-catenin in inflammatory bowel disease-related oncogenesis. Peptides. 2007;28:2030–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer. 1999;80:448–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Gui X, Guzman G, Dobner PR, Kadkol SS. Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides. 2008;29:1609–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71.CrossRefPubMedGoogle Scholar
  17. 17.
    Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119:1219–27.CrossRefPubMedGoogle Scholar
  18. 18.
    Müller KM, Tveteraas IH, Aasrum M, Odegard J, Dawood M, Dajani O, et al. Role of protein kinase c and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC Cancer. 2011;11:421.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Potten CS, Booth C, Pritchard DM. The intestinal epithelial stem cell: the mucosal governor. Int J Exp Pathol. 1997;78:219–43.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Souaze F, Viardot-Foucault V, Roullet N, Toy-Miou-Leong M, Gompel A, Bruyneel E, et al. Neurotensin receptor 1 gene activation by the TCF/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis. 2006;27:708–16.CrossRefPubMedGoogle Scholar
  21. 21.
    van Eeden SF, Terashima T. Interleukin 8 (IL-8) and the release of leukocytes from the bone marrow. Leuk Lymphoma. 2000;37:259–71.PubMedGoogle Scholar
  22. 22.
    Wang X, Wang Q, Ives KL, Evers BM. Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res. 2006;12:5346–55.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Gully D, Labeeuw B, Boigegrain R, Oury-Donat F, Bachy A, Poncelet M, et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther. 1997;280:802–12.PubMedGoogle Scholar
  24. 24.
    Mazella J, Botto JM, Guillemare E, Coppola T, Sarret P, Vincent JP. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J Neurosci. 1996;16:5613–20.PubMedGoogle Scholar
  25. 25.
    Mazella J, Vincent JP. Functional roles of the NTS2 and NTS3 receptors. Peptides. 2006;27:2469–75.CrossRefPubMedGoogle Scholar
  26. 26.
    Leeman SE, Carraway RE. Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. Ann N Y Acad Sci. 1982;400:1–16.CrossRefPubMedGoogle Scholar
  27. 27.
    Kitabgi P. Inactivation of neurotensin and neuromedin N by Zn metallopeptidases. Peptides. 2006;27:2515–22.CrossRefPubMedGoogle Scholar
  28. 28.
    Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update. CA Cancer J Clin. 2010;60:70–98.CrossRefPubMedGoogle Scholar
  29. 29.
    Martin S, Navarro V, Vincent JP, Mazella J. Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology. 2002;123:1135–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Mantuano E, Santi S, Filippi C, Manca-Rizza G, Paoletti S, Consani C, et al. Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Biomed Pharmacother. 2007;61:360–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Malicki S, Winiarski M, Matlok M, Kostarczyk W, Guzdek A, Konturek PC. Il-6 and il-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol. 2009;60:141–6.PubMedGoogle Scholar
  32. 32.
    Sakoda K, Yamamoto M, Negishi Y, Liao JK, Node K, Izumi Y. Simvastatin decreases il-6 and il-8 production in epithelial cells. J Dent Res. 2006;85:520–3.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • George Sgourakis
    • 1
  • Aggeliki Papapanagiotou
    • 2
  • Christos Kontovounisios
    • 1
  • Michalis V. Karamouzis
    • 2
  • Georgia Dedemadi
    • 1
  • Constantine Goumas
    • 3
  • Constantine Karaliotas
    • 1
  • Athanasios G. Papavassiliou
    • 2
  1. 1.Second Department of Surgery and Surgical Oncology UnitRed Cross HospitalAthensGreece
  2. 2.Department of Biological ChemistryUniversity of Athens Medical SchoolAthensGreece
  3. 3.Department of GastroenterologyRed Cross HospitalAthensGreece

Personalised recommendations